Hekimian L J, Weise C C, Friedhoff A J
J Clin Psychiatry. 1983 Jul;44(7):248-52.
In a parallel-group double-blind study, 142 outpatients with "mixed anxiety/depression" were treated with amoxapine or doxepin for 4 weeks in mean maximum daily dosages of 260 mg and 130 mg, respectively. Patients in both groups improved significantly during treatment as shown by changes in the Hamilton, Zung, Patient Self-Evaluation, and Clinical Global Impressions scales. From 24 to 31 of the 71 subjects receiving amoxapine and 16 to 24 of the 71 receiving doxepin were rated as "unquestionably improved" at the end of the treatment period on these scales. The time to achieve this degree of response was significantly shorter with amoxapine on both the CGI (p = .018) and Hamilton (p = .005) scales. Side effects were roughly comparable with two exceptions: doxepin-treated patients experienced more daytime drowsiness (p less than or equal to .05) and amoxapine-treated patients experienced more constipation (p less than or equal to .01).
在一项平行组双盲研究中，142名患有“混合性焦虑/抑郁”的门诊患者分别接受阿莫沙平或多塞平治疗4周，平均最大日剂量分别为260毫克和130毫克。两组患者在治疗期间均有显著改善，汉密尔顿、zung、患者自我评估和临床总体印象量表的变化表明了这一点。在治疗期结束时，接受阿莫沙平治疗的71名受试者中有24至31人、接受多塞平治疗的71名受试者中有16至24人在这些量表上被评为“明显改善”。在临床总体印象量表（p = 0.018）和汉密尔顿量表（p = 0.005）上，阿莫沙平达到这种反应程度的时间明显更短。副作用大致相当，但有两个例外：接受多塞平治疗的患者白天嗜睡更多（p≤0.05），接受阿莫沙平治疗的患者便秘更多（p≤0.01）。
